Article: Coronavirus in China: 2021 outlook brightens for health care operators, pharmaceutical and device makers after price cuts

Article Details

Impact Score

5 / 10

AI Summary (Processed Content)

Financial analysts forecast a positive 2021 for China's hospital operators and internet healthcare platforms, as pandemic impacts wane and policy reforms encourage online services.

However, pharmaceutical and medical device manufacturers face challenges from price pressures due to China's new centralized procurement system.

The healthcare sector performed strongly in 2020, with major stock indices seeing significant gains driven by pandemic-fueled demand for online health services.

Main topics: China healthcare sector outlook, hospital and internet platform operators, drug price pressures, 2020 stock performance.

Original URL

https://www.scmp.com/business/companies/article/3116183/coronavirus-china-2021-outlook-brightens-health-care-operators?utm_source=rss_feed

Source Feed

Science & Research - South China Morning Post

Published Date

2021-01-03 01:45

Fetched Date

2026-03-04 14:31

Processed Date

2026-03-04 15:17

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

Coronavirus in China: 2021 outlook brightens for health care operators, pharmaceutical and device makers after price cuts
- Hospital operators, internet-platform owners are likely to be among winners in 2021 as the pandemic impact wanes, Citigroup says
- Price pressures could hit drug and device manufacturers as China imposed new centralised procurement system
While vaccine deployment is certain to hog the limelight, Citigroup said internet platform operators can profit from ongoing policy reforms to spur greater adoption of online services and reduce hospital trips. Pressure on drug prices is a key challenge to market players, China Renaissance Securities said.
“We expect hospital operators to see better fortunes,” Cui Cui, head of China health care research at Citigroup, said in an interview with South China Morning Post. “Pharmaceutical firms whose new drug sales ramp-up has been slower than expected due to disruptions should also benefit, while internet health care platform operators should continue to do well.”
An MSCI index tracking 81 Chinese health care stocks with a combined market value of HK$1.15 trillion (US$148 billion) advanced 61 per cent in 2020, the biggest gain since 2003 as the pandemic fuelled online delivery channels. WuXi Biologics, the biggest constituent with 20.5 per cent weight, surged 213 per cent, making it the top performer among all Hong Kong-listed stocks.
A separate gauge for 80 mainland-listed players climbed 29.4 per cent in 2020. The biggest member, Jiangsu Hengrui Medicine, gained 53 per cent after a near-doubling in 2019, according to Bloomberg data.